Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Long-Term Deferred Tax (2016 - 2026)

United Therapeutics' Long-Term Deferred Tax history spans 17 years, with the latest figure at $357.7 million for Q4 2025.

  • On a quarterly basis, Long-Term Deferred Tax fell 21.97% to $357.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $357.7 million, a 21.97% decrease, with the full-year FY2025 number at $357.7 million, down 21.97% from a year prior.
  • Long-Term Deferred Tax hit $357.7 million in Q4 2025 for United Therapeutics, up from $354.9 million in the prior quarter.
  • Over the last five years, Long-Term Deferred Tax for UTHR hit a ceiling of $458.4 million in Q4 2024 and a floor of $261.9 million in Q4 2021.
  • Historically, Long-Term Deferred Tax has averaged $342.7 million across 5 years, with a median of $326.6 million in 2022.
  • Biggest five-year swings in Long-Term Deferred Tax: grew 25.12% in 2022 and later decreased 21.97% in 2025.
  • Tracing UTHR's Long-Term Deferred Tax over 5 years: stood at $261.9 million in 2021, then increased by 25.12% to $327.7 million in 2022, then rose by 20.48% to $394.8 million in 2023, then increased by 16.11% to $458.4 million in 2024, then decreased by 21.97% to $357.7 million in 2025.
  • Business Quant data shows Long-Term Deferred Tax for UTHR at $357.7 million in Q4 2025, $354.9 million in Q3 2025, and $456.2 million in Q2 2025.